Related Experiment Video
Updated: Jan 15, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Mechanistic data-informed multiscale quantitative systems pharmacology modeling framework enables the clinical
Siyuan Yang1, Wenjie Wang2, Qi Rao1
1School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China.
Background:
Chimeric antigen receptor (CAR)-T cell therapy represents an innovative and potentially revolutionary modality in cancer treatment. Despite their great success in treating blood cancers, CAR-T therapies exhibit significantly lower effectiveness in treating solid tumors. Moreover, the preclinical-to-clinical translation of CAR-T therapies targeting solid tumors is still a challenging task because of their unique "live cell" nature and the substantial variability in patients' pathophysiology.
Methods:
We have developed a multiscale quantitative systems pharmacology (QSP) model to facilitate the clinical translation of CAR-T therapies in solid tumors. Our mechanistic modeling framework integrates the essential biological features that impact CAR-T cell fate and antitumor cytotoxicity, from cell-level CAR-antigen interaction and activation, to in vivo CAR-T biodistribution, proliferation and phenotype transition, and finally to clinical-level patient tumor heterogeneity and response variability. This modeling framework has been calibrated and validated by multimodal experimental data including published preclinical and clinical data of various CAR-T products and original preclinical data of a novel claudin18.2-targeted CAR-T product LB1908.
Results:
We demonstrated the general utility of this framework in facilitating clinical translation and characterizing the paired cellular kinetics-cytotoxicity response of different antigen-targeting solid tumor CAR-T cell therapies. As an example, we generated model-based virtual patients and prospectively simulated the response to claudin18.2-targeted CAR-T therapies under different dosing strategies, including step-fractionated dosing and convenient flat dose-based regimens, to inform future clinical trial implementation.
Conclusions:
Our translational QSP platform offers an innovative pathway to integrate multiscale knowledge and inform clinical decision-making of novel solid tumor-targeting CAR-T therapies.
Insights
Quantitative systems pharmacology (QSP) models can improve chimeric antigen receptor (CAR)-T cell therapy for solid tumors. This approach integrates biological factors to predict CAR-T cell behavior and patient response, aiding clinical translation.
Area of Science:
- Immunology
- Pharmacology
- Computational Biology
Background:
- Chimeric antigen receptor (CAR)-T cell therapy shows promise in cancer treatment but faces challenges in solid tumors.
- Preclinical to clinical translation of CAR-T therapies for solid tumors is hindered by cell-specific factors and patient variability.
Purpose of the Study:
- To develop a multiscale quantitative systems pharmacology (QSP) model for facilitating the clinical translation of CAR-T therapies in solid tumors.
- To integrate essential biological features influencing CAR-T cell fate and antitumor cytotoxicity.
Main Methods:
- Developed a mechanistic QSP modeling framework integrating cell-level interactions, in vivo dynamics, and patient-specific factors.
- Calibrated and validated the model using multimodal preclinical and clinical data, including a novel claudin18.2-targeted CAR-T product (LB1908).
Main Results:
- Demonstrated the framework's utility in facilitating clinical translation and characterizing CAR-T cell kinetics-cytotoxicity responses in solid tumors.
- Generated model-based virtual patients to simulate responses to claudin18.2-targeted CAR-T therapies under various dosing strategies, informing clinical trial design.
Conclusions:
- The developed translational QSP platform integrates multiscale knowledge for informed clinical decision-making in solid tumor CAR-T therapies.
- This approach offers an innovative pathway to advance CAR-T cell therapy for solid tumors.
Related Concept Videos
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
01:15Model Approaches for Pharmacokinetic Data: Physiological Models
01:14Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
01:21Mechanistic Models: Overview of Compartment Models
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:14Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...